Pfiz­er dumps a fad­ing pipeline star, giv­ing up on its PC­SK9 drug bo­co­cizum­ab

You can scratch any hopes you might have had that Pfiz­er could mount a come-from-be­hind win and seize the lead from Am­gen and Sanofi/Re­gen­eron in the race of PC­SK9 cho­les­terol drugs. The phar­ma gi­ant has de­cid­ed to drop its can­di­date, bo­co­cizum­ab, cit­ing wan­ing ef­fi­ca­cy re­sults, a poor mar­ket re­cep­tion for the pi­o­neers, signs of an im­mune re­sponse to the drug and side ef­fects that would have like­ly marred its de­but.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER